Knight Therapeutics | GUD - Selling And Administration Expenses


Knight Therapeutics reported CAD35.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Canopy Growth CAD 31.17M 2.27M Mar/2026
Cronos Group USD 17.35M 2.1M Mar/2026
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Moderna USD 216M 43M Jun/2026
Omeros USD 11.32M 2.48M Sep/2024
Organigram Holdings CAD 22.01M 14.28M Mar/2026
Organon & Co USD 424M 9M Mar/2026
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026